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Protozoan parasites belonging to the genus Trypano-
soma are responsible for two major infections in humans; 
namely, Chagas disease (or American trypanosomiasis) 
and human African trypanosomiasis (HAT), which is 
the sleeping sickness. Estimates indicate that more than 
10 million people worldwide are infected by the caus-
ative agents, Trypanosoma cruzi and Trypanosoma bru-
cei, resulting in considerable morbidity and mortality, 
especially in developing countries (Barrett et al. 2003, 
WHO 2010, Wilkinson et al. 2011). Current therapies 
targeting these pathogens have proven to be unsatisfac-
tory because of many of these therapeutic agents have 
limited efficacy, some serious side effects and resistance 
in the clinical context has emerged (Castro et al. 2006, 
Wilkinson & Kelly 2009, Rassi-Jr et al. 2012). In addi-
tion, in HAT intravenous administration of drugs, the 
time required to complete the course of treatment and the 
cost associated with them remain highly limiting (Bar-
rett et al. 2003, Nwaka & Hudson 2006). Chagas disease 
treatment is focused on the use of two nitroheterocyclic 
prodrugs: nifurtimox (1), a 5-nitrofuran and benznida-
zole (2), a 2-nitroimidazole (Fig. 1). Neither of these 
agents is ideal due to undesirable secondary side effects. 
Variable results have been observed with these agents 
depending on the phase of the disease (they are only ef-
fective in the acute and recent chronic phases of the in-
fection), the dose and duration of treatment, the patient’s 
age and the endemic region (Castro et al. 2006, Soeiro & 
de Castro 2011). Five approved treatments for HAT exist, 
including four monotherapies, pentamidine (3), suramin 
(4), melarsoprol (5) and eflornithine (6) (Fig. 1) and a 
nifurtimox-eflornithine combination therapy. Benefits 
and disadvantages have been associated with each medi-
cation (Wilkinson & Kelly 2009, Jacobs et al. 2011). The 
arsenical compound melarsoprol (5) is of particular note, 
as it is highly toxic, causing reactive encephalopathy in 
5-10% of treated patients, of which, 50% will die as a 
result of this adverse reaction (El-Sayed et al. 2005, Bo-
lognesi et al. 2008). Despite these drawbacks, melarso-
prol (5) is still in use and represents the only drug that 
can target the neurological phase of all cases of African 
sleeping sickness.
Megazol (7) is a 5-nitroimidazole that contains a 
1,3,4-thiadiazole substituent group at position 2 (Fig. 
2) and displays significant activity against a wide range 
of microbes. When screened on trypanosomes, it was 
shown to be more effective against T. cruzi than com-
pounds 1 or 2, displaying activity towards strains that 
were refractory to these two nitroheterocycles (Filardi & 
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Megazol (7) is a 5-nitroimidazole that is highly active against Trypanosoma cruzi and Trypanosoma brucei, as 
well as drug-resistant forms of trypanosomiasis. Compound 7 is not used clinically due to its mutagenic and geno-
toxic properties, but has been largely used as a lead compound. Here, we compared the activity of 7 with its 4H-1-
,2,4-triazole bioisostere (8) in bloodstream forms of T. brucei and T. cruzi and evaluated their activation by T. brucei 
type I nitroreductase (TbNTR) enzyme. We also analysed the cytotoxic and genotoxic effects of these compounds in 
whole human blood using Comet and fluorescein diacetate/ethidium bromide assays. Although the only difference 
between 7 and 8 is the substitution of sulphur (in the thiadiazole in 7) for nitrogen (in the triazole in 8), the results 
indicated that 8 had poorer antiparasitic activity than 7 and was not genotoxic, whereas 7 presented this effect. The 
determination of Vmax indicated that although 8 was metabolised more rapidly than 7, it bounds to the TbNTR with 
better affinity, resulting in equivalent kcat/KM values. Docking assays of 7 and 8 performed within the active site of a 
homology model of the TbNTR indicating that 8 had greater affinity than 7.
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Brener 1987). It also displayed considerable growth in-
hibitory activity against T. brucei, in which it was dem-
onstrated to promote parasite clearance in animals after 
the administration of a single dose (Bouteille et al. 1995, 
Enanga et al. 1999, 2000).
These initial results have stimulated research aimed 
at revealing the mechanism by which compound 7 me-
diates its antiparasitic activities. Several studies have 
clearly indicated that compound 7 enters the parasite by 
passive diffusion (Barrett et al. 2003) and once inside the 
cell, it undergoes activation by nitroreductase enzymes 
(NTR). These enzymes catalyse one or two electron re-
duction of the conserved nitro group found on the imi-
dazole ring (Viodé et al. 1999, Wilkinson & Kelly 2009). 
The subsequent downstream mechanisms account-
ing for the mode of action of compound 7 are unclear. 
Based on studies using T. cruzi, it has been proposed 
that compound 7 may interfere with oxygen metabolism 
(Viodé et al. 1999), possibly by affecting intracellular 
thiol levels, especially trypanothione (Maya et al. 2003) 
and/or via the inhibition of NADH fumarate reductase 
activity (Turrens et al. 1996). Alternatively, compound 
7 has clearly been shown to mediate DNA damage in 
T. brucei mutants lacking RAD51, a key component of 
the parasite’s homologous DNA repair pathway (Enanga 
et al. 2003). Subsequent reports provided evidence that 
compound 7 was mutagenic in a bacterial Ames assay 
(Ferreira & Ferreira 1986) and promoted chromosomal 
aberrations in mammalian cells (Nesslany et al. 2004). 
Further investigations into using this compound as a try-
panocidal agent were discontinued. Thus, compound 7 is 
a promising target compound that can be used to search 
for new analogs that lack these side effects.
Nowadays, many efforts have been done in the search 
of new synthetic lead compounds such as triazoles, qui-
nolines and others (Papadopoulou et al. 2011, 2013, da 
Silva et al. 2012) and synthetic nitroimidazole deriva-
tives (Mital 2009, Paula et al. 2009).
Our research group has been conducting studies with 
this aim in mind (Boechat et al. 2001, Carvalho et al. 
2004, 2006, 2007, 2008, Salomão et al. 2010) and we 
have identified several promising prototypes (Boechat 
et al. 2001, Carvalho et al. 2004, 2006, 2007, 2008). The 
triazole nucleus is one of the most important heterocy-
cles and has well-known trypanocidal activity (Boechat 
et al. 2012). Using a triazole nucleus as an isostere of 
thiadiazole, which is contained in the megazol proto-
type, we synthesised 5-(1-methyl-5-nitro-1H-imidazol-
2-yl)-4H-1,2,4-triazol-3-amine (8), as shown in Fig. 2 
(Carvalho et al. 2007). Unfortunately, a dramatic loss 
of activity against T. cruzi was observed. However, the 
results of a preliminary cytotoxicity study revealed that 
compound 8 was not toxic, encouraging us to study the 
physical-chemical and biological properties of bioisos-
tere 8. Our goal is not only to find active compounds 
against T. cruzi and T. brucei, but also explore the so 
well documented relationship of the nitro group with the 
biological and mutagenic activities. Thus, the purpose of 
the present study was to compare the in vitro activities 
of bioisosteres 7 and 8 in T. cruzi and T. brucei, as well 
as their genotoxicity and cytotoxicity. We also aimed to 
study the in vitro and in silico activation process of these 
compounds by NTR of T. brucei (TbNTR).
SUBJECTS, MATERIALS AND METHODS
Chemistry - Benznidazole (2) was provided by Hoff-
mann-La Roche Inc. Megazol (7) and its bioisostere 
5-(1-methyl-5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-
3-amine (8) was synthesised from 2-cyano-5-nitroimi-
dazole by condensation in trifluoroacetic acid with thi-
osemicarbazide to generate the thiadiazole ring or with 
aminoguanidine to generate the triazole ring, as previ-
ously described (Carvalho et al. 2007).
Parasites - T. cruzi (Y strain) bloodstream form 
(BSF) trypomastigotes were obtained from infected 
male Swiss Webster mice (18-20 g in body weight) at 
the peak of parasitaemia and isolated using differential 
centrifugation (de Castro et al. 1987). T. brucei brucei 
(MITat 427 strain; clone 221a) BSF trypomastigotes 
were grown at 37ºC under a 5% (v/v) CO2 atmosphere 
in modified Iscove’s medium, as previously described 
(Hirumi & Hirumi 1989).
T. cruzi BSF were suspended to a concentration of 
1 x 107 parasites mL-1 in Dulbecco’s modified Eagle’s 
medium containing 10% (v/v) foetal calf serum. This 
suspension (100 μL) was added to the same volume of 
compound 7 or 8, which had been previously prepared 
at double the desired final concentrations in 96-well mi-
croplates and was incubated for 24 h at 37ºC under a 5% 
Fig. 1: chemical structures of nifurtimox (1) and benznidazole (2), the 
drugs currently used to treat Chagas disease, and pentamidine (3), 
suramin (4), melarsoprol (5) and eflornithine (6), the agents currently 
used to treat African sleeping sickness.
Fig. 2: chemical structures of megazol (7) and its triazole analog [5-(1-
methyl-5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine (8)].
317Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 109(3), May 2014
(v/v) CO2 atmosphere. Cell counts were then carried out 
using a Neubauer chamber and the compound concen-
tration that killed 50% of the parasites (LD50) was de-
termined. Untreated and benznidazole-treated parasites 
were used as controls.
T. brucei BSF were seeded at 1 x 103 parasites mL-1 in 
growth medium containing different concentrations of 
compound 7 or 8 and aliquots (200 μL) were dispensed 
into the wells of 96-well microplates. After incubation at 
37ºC for three days, alamarBlue™ (20 µl) (Life Technol-
ogies Ltd, Paisley, UK) was added to each well and the 
plates were incubated for another 16 h. The fluorescence 
of each culture was then determined using a Gemini 
fluorescent plate reader (Molecular Devices Ltd, Wok-
ingham, UK) at an excitation wavelength of 530 nm, an 
emission wavelength of 585 nm and a filter cut-off at 550 
nm. The colour change resulting from dye reduction is 
proportional to the number of live cells. The concentra-
tion of each compound that inhibited parasite growth by 
50% (IC50) was then established.
Enzyme activity of the TbNTR - Enzyme activity was 
measured spectrophotometrically by following NADH 
oxidation (λ = 340 nm; ε = 6,220 M-1cm-1) using recombi-
nant TbNTR, which had been purified as previously de-
scribed (Hall et al. 2010). A standard reaction mixture (1 
mL) containing 50 mM Tris-Cl, pH 7.5, NADH (100 µM) 
and substrate (0-200 µM) was incubated at room tem-
perature (RT) for 5 min. The background rate of NADH 
oxidation was determined and the reaction was initiated 
by the addition of trypanosomal enzyme (20 µg). The re-
sults were evaluated via a non-linear regression analysis 
using GraphPad Prism 5 (GraphPad Software).
Toxicity to whole blood - Heparinised human blood 
was obtained by venipuncture immediately prior to the 
assays. Whole blood was treated for 2 h at 37ºC with 
different concentrations of compounds 7 (380-4000 
µM) or 8 (149-6400 µM) in 5% (v/v) dimethyl sulfoxide 
(DMSO) (solvent-control) and then used in the assays. 
Cell viability was determined at the end of drug treat-
ment using the fluorescein diacetate (FDA)/ethidium 
bromide (EtBr) assay (Hartmann & Speit 1997). Whole 
blood (50 µL) was mixed with an equal volume of the 
freshly prepared staining solution, which consisted of 30 
µg/mL of FDA plus 8 µg/mL of EtBr in phosphate buff-
ered saline (PBS). The samples (50 µL) were spread on 
microscope slides and covered with coverslips. Viable 
cells appeared as green-fluorescent, whereas orange-
stained nuclei indicated dead cells. A total of 200 cells 
were analysed for each treatment.
Genotoxicity in an in vitro alkaline Comet assay - 
DNA damage in whole blood was evaluated at the end 
of a 2 h treatment in duplicate with compound 7 or 8, at 
the same concentrations indicated above using the alka-
line Comet assay (Tice et al. 2000, Speit & Hartmann 
2006). Methyl methane-sulfonate (MMS) (160 µM) Mil-
waukee, WI, USA) was used as a positive control. Al-
iquots of 5 µL of whole blood were mixed with 120 µL 
of 0.5% (w/v) low melting-point agarose (LMPA) in PBS 
(Sigma-Aldrich, St. Louis, MO, USA) at 37ºC and added 
to microscope slides that had been previously covered 
with 1.5% (w/v) normal melting-point agarose (Sigma-
Aldrich). Four slides per treatment were prepared (2 slides 
per culture). Immediately afterward, the slides were cov-
ered with a coverslip and after LMPA solidification for 
3 min at 4-5ºC, the coverslips were removed. The slides 
were then immersed in cold lysis buffer [2.5 M NaCl, 100 
µM mM Na2 ethylenediamine tetraacetic acid (EDTA), 
10 mM µM Tris, 1% (w/v) N-lauroylsarcosine sodium 
salt, 1% (v/v) Triton X-100 and 10% (v/v) DMSO, pH 10] 
for a minimum of 1 h at 4ºC and protected from light. The 
slides were placed on a horizontal gel electrophoresis unit 
that had been filled with freshly made alkaline buffer at 
a pH > 13 (300 mM NaOH and 1 mM EDTA). The dura-
tion of alkali exposure and DNA electrophoresis (0.86 V/
cm and 300 mA) was 20 min each in an ice bath. The 
samples were neutralised by washing them three times (5 
min per wash) in Tris buffer (0.4 M Tris, pH 7.5), drained, 
fixed in absolute ethanol [99.8% (v/v)] for approximately 
10 min and left at RT overnight to dry. EtBr (30 µL of a 
20 µg/mL stock) was then added to each slide. The slide 
was then covered with a coverslip and analysed using a 
fluorescence microscope at 400X magnification. Fifty 
randomly selected cells per slide (200 cells per treatment) 
were analysed visually and divided into one of four DNA 
damage classes based on tail size: 0 (undamaged; i.e., no 
visible tail), 1 (slightly damaged), 2 (moderately dam-
aged) and 3 (maximally damaged; i.e., the head of the 
comet was very small and the majority of the DNA was in 
the tail). The DNA damage was expressed as the percent-
age of cells in four classes and as arbitrary units (AU) ac-
cording to the formula: AU = (0 x nº of comets in Class 0) 
+ (1 x nº of comets in Class 1) + (2 x nº of comets in Class 
2) + (3 x nº of comets in Class 3). The total DNA damage 
score in AU (TAU) for 200 comets can range from 0 TAU 
(undamaged) to 600 TAU (maximally damaged). Differ-
ences between the mean values of TAU from three and 
two independent experiments under the same conditions, 
respectively, for each concentration of compounds 7 and 
8 were tested for significance (p < 0.05) in relation to the 
solvent-control group using Student’s one-tailed t test. In 
addition, the effects of megazol and compound 8 on the 
intercellular distribution of DNA damage were tested for 
statistical significance using one-way ANOVA, followed 
by a Dunnett’s multiple comparison test to compare each 
concentration of the compounds.
Molecular modelling - Theoretical calculations were 
carried out to investigate the stereoelectronic properties 
of megazol and compound 8 and were aimed to charac-
terise the electronic features of the designed molecules 
that may be important for their bioactivity. The highest 
occupied molecular orbital (HOMO) and lowest unoc-
cupied molecular orbital (LUMO) energies were calcu-
lated using the MOPAC2009 software package (Open-
MOPAC.net) using the semiempirical PM3 method with 
the full geometry optimisation. The ejection fraction 
(EF) routine was used for the minimum search. Default 
values were taken for the other parameters. The Carte-
sian coordinates of megazol and compound 8 were built 
using the Avogadro Program (Hanwell et al. 2012).
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So far, no experimental (NMR or crystallographic) 
structure of the TbNTR is available in the Protein Data 
Bank (PDB) (Bernstein et al. 1977). Therefore, the con-
struction of a homology model was necessary for the 
docking studies. The amino acid sequence of the TbNTR 
was retrieved from the National Center for Biotechnolo-
gy Information (Geer et al. 2010) under the XP_846343.1 
code. This sequence was subsequently blasted against 
the PDB, yielding structures belonging to the nitro-
flavin mononucleoside (FMN)-reductase superfamily. 
The crystal structure of the nitroreductase family pro-
tein from Streptococcus pneumoniae Tigr4 (PDB code 
2B67) (Kim et al. 2011) and the structure of Escherichia 
coli nitroreductase bound to the antibiotic nitrofura-
zone (PDB code 1YKI) (Race et al. 2005) were used as 
templates. The multiple-sequence alignment between 
the target and the templates was carried out using the 
Multiple Alignment using Fast Fourier Transform server 
(Katoh et al. 2002).
The homology model was built using the Modeller 
9.v.8 program (Eswar et al. 2006) and the resulting struc-
ture was submitted for evaluation to the Swiss-model 
workspace (Arnold et al. 2006).
Docking experiments of megazol and compound 8 in 
the active site of the modelled TbNTR were performed 
using AutoDock VINA software (Trott & Olson 2010). 
Gasteiger-Hückel charges and AutoDock (Morris et al. 
1996) molecular mechanics force fields were used. One 
hundred solutions were generated for each compound 
using different pseudorandom seeds. In each run 200 
binding modes were created, out of which only the top 
20, ranked by the VINA scoring function, were acces-
sible to the user. The search was conducted in a cubic 
volume of 25 x 25 x 25 Å3, centred on the coordinates of 
the crystallographic compound, with a value of 150 for 
exhaustiveness.
All calculations were carried out on an Intel® CoreTM i5 
CPU machine and graphics were generated using the Jmol 
(jmol.org/) and PyMOL (pymol.org/) software packages.
Ethics - All experiments were carried out in accor-
dance with the guidelines established by the Oswaldo 
Cruz Foundation Ethical Committee for the Use of Ani-
mals (LW 16-13).
RESULTS
Megazol (7) and its bioisostere 5-(1-methyl-5-nitro-
1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine (8) were 
synthesised from 2-cyano-5-nitroimidazole as previ-
ously described (Carvalho et al. 2007).
To evaluate whether the TbNTR could metabolise 
compounds 7 and 8 (compound 2 was also tested), re-
combinant protein was purified from E. coli cells and 
then used in NADH-based oxidation assays containing 
the nitroimidazole as a substrate (Hall et al. 2010). These 
results can be found in Table.
The biological activities of compounds 7 and 8 were 
then evaluated in parasitic and mammalian cells (Table).
The cytotoxicity of compounds 7 and 8 and their 
ability to induce DNA damage in human blood cells are 
described in Fig. 3, Table and the degree of damage are 
in Fig. 4.
Theoretical calculations for the HOMO and the 
LUMO frontier orbitals revealed that the HOMO ener-
gies were -9.42 and -9.62 eV and that the LUMO energies 
were -1.64 and -1.72 eV for compounds 7 and 8, respec-
tively (Fig. 5).
DISCUSSION
Most nitroheterocyclic compounds act as prodrugs 
and must be activated before their cytotoxic effects can 
be evaluated. Initially, it was proposed that trypanocidal 
action occurs by inducing oxidative stress through the 
one-electron reduction of its nitro group and the subse-
quent formation of superoxide by a futile cycle. However, 
more recent studies have indicated that this process does 
not occur to an extent that would be toxic to the parasites 
and that a type I NTR is responsible for the trypanocid-
al activity of nifurtimox (1) and benznidazole (2). This 
enzyme has been shown to play a key role in activating 
many other antitrypanosomal nitroheterocyclic drugs 
(Wilkinson & Kelly 2009, Bot et al. 2010, Hall et al. 2010). 
NTR mediates a series of two-electron reduction reac-
tions, resulting in the fragmentation of the heterocyclic 
ring and the production of toxic metabolites. Because the 
type I NTR, which is absent in most eukaryotes except 
trypanosomes, can catalyse the activation of nitrohetero-
cyclic prodrugs, these compounds have been investigated 
TABLE












7 9.9 ± 0.8 0.14 ± 0.01 475.7 ± 21 4.0 x 104 p < 0.01 Absence
8 256.8 ± 53.0 > 40.0 768.8 ± 28 2.4 x 104 Absence Absence
2 23.8 22.1 ± 0.9 625.4 ± 50 2.6 x 103 ND ND
a: activity expressed as µmol NADH oxidised min-1mg-1; b: expressed as M-1s-1; compound 2: benznidazole; compound 7: mega-
zol; compound 8: 5-(1-methyl-5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine; IC: inhibitory concentration; LD50: lethal 
dose; ND: not determined; TbNTR: nitroreductase enzymes of T. brucei.
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for their application as antiparasitic agents (Wilkinson & 
Kelly 2009, Bot et al. 2010, Hall et al. 2010).
To evaluate whether the TbNTR could metabolise 
compounds 7 and 8 (compound 2 was also tested), re-
combinant protein was purified from E. coli cells and 
then used in NADH-based oxidation assays containing 
the nitroimidazole as a substrate (Hall et al. 2010). This 
test demonstrated that the parasite enzyme metabo-
lised all three of the compounds evaluated. Based on 
the enzyme kinetic values, the activity (apparent Vmax) 
indicated that compound 8 was metabolised at a faster 
rate than compound 7, it bounds to the TbNTR with a 
greater affinity, resulting in these two compounds hav-
ing equivalent kcat/KM values (Table). Interaction of the 
TbNTR with compound 2 indicated that although a rea-
sonable Vmax value was generated, this 2-nitroimidazole 
displayed the lowest affinity for the parasite enzyme of 
the compounds screened, resulting in a kcat/KM value 
that was one order of magnitude lower than that of the 
5-nitroimidazole-based agents.
When tested in T. brucei, compound 8 did not affect 
the growth of BSF cells (40 µM was the upper limit used 
in these experiments), whereas compound 7 significant-
ly inhibited BSF proliferation, with an IC50 value of 0.14 
µM. A similar trend was observed when the activities of 
compounds 7 and 8 in T. cruzi were investigated: both 
compounds killed the parasites, with the LD50 of com-
pound 7 being 25-fold lower than that of compound 8. 
These disparities in the trypanocidal activity of the two 
compounds may indicate differences in their uptake by 
the parasites or may suggest that once in the pathogen 
the two compounds have distinct mechanisms of action, 
since those compound 8 bonds to the TbNTR with high-
er affinity.
The alkaline Comet assay (single cell gel electropho-
resis assay) combines the simplicity of biochemical tech-
niques that detect DNA single and double-strand breaks 
and alkali-labile sites with a single cell approach, which 
is typical of cytogenetic assays (Singh et al. 1988). The 
advantages of this assay include its sensitivity in detect-
Fig. 3: DNA damage induction in human whole blood as analysed using the Comet assay. A: megazol (7) (n = 3); B: triazole analog [5-(1-methyl-
5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine (8)] (n = 2). The white bars correspond to the untreated control culture and the solvent-
control [5% (v/v) dimethyl sulfoxide (DMSO)], the grey bars correspond to the tested compounds and the black bars correspond to the positive 
control (160 µM methyl methane-sulfonate). The bars represent the standard error of the means of the total arbitrary units (AU). For Student’s 
one tailed t test, the asterisks indicate significance at 1% (**) and 0.1% (***) levels. compound 7: megazol; compound 8: 5-(1-methyl-5-nitro-
1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine.
Fig. 4: intercellular distribution of DNA damage in human whole blood, as analysed using the Comet assay. A: megazol (7) at concentrations 
of 380, 611, 976, 1,562, 2,500 and 4,000 µM (arrows) (n = 3); B: the triazole analog [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-
3-amine (8)] at concentrations of 149, 238, 382, 610, 977, 1,562, 2,500, 4,000 and 6,400 µM (arrows) (n = 2). The white bars correspond to 
the untreated control culture and the solvent-control [5% (v/v) dimethyl sulfoxide], the grey bars correspond to the tested compounds and the 
black bars correspond to the positive control (160 µM methyl methane-sulfonate). The bars represent the standard error of the mean frequency 
(%) of the cells in the different classes of DNA damage. For the Dunnett’s test, the asterisks indicate significance at 5% (*), 1% (**) and 0.1% 
(***) levels.
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ing DNA damage, the ability to analyse data at the level of 
the individual cell and the ability to use extremely small 
cell samples (Anderson et al. 1998, Speit & Hartmann 
2006, Lynch et al. 2011). Using the Comet and FDA/EtBr 
assays, we compared the cytotoxicity of compounds 7 
and 8 and their ability to induce DNA damage in human 
blood cells (Fig. 3). When high concentrations (> 1,500 
µM) of compound 7 were used, significant (p < 0.01) 
DNA damage was detected in whole blood cells com-
pared to treatment with 5% (v/v) DMSO alone; cells that 
had been incubated with MMS (0.16 µM) also displayed 
DNA damage. The degree of damage was quantified by 
comparing the amount of DNA in the comet head with 
that present within the tail (see the Materials and Meth-
ods section) (Fig. 4). In this system, Class 0 is equivalent 
to no DNA damage (with the entire nuclear DNA con-
tained within the comet head and no visible tail), while 
Class 3 corresponds to maximum damage (with little 
DNA in the comet head and the majority contained in 
the tail). Classes 1 and 2 represent intermediate levels of 
damage, such that Class 1 indicates slight damage and 
Class 2 indicates moderate damage. In cells treated with 
2,500 or 4,000 µM concentrations of compound 7, sig-
nificant (p < 0.05) Class 1 (42% for 4,000 µM) and highly 
significant (p < 0.01) Class 2 (11% and 14% for 2,500 and 
4,000 µM, respectively) of damage were observed, with 
some of the cells displaying Class 3 (12%) DNA damage. 
In contrast, significant Class 3 damage was detected fol-
lowing treatment with MMS (1,600 µM), with 54% of the 
cells displaying this level of damage. The genotoxicity 
observed following treatment with high concentrations 
of compound 7 was not associated with cytotoxicity, as 
whole blood cell viability studies using 1,562 µM, 2,500 
µM and 400 µM concentrations resulted in 5%, 7% and 
9% of cells being non-viable, respectively; under the 
same conditions, treatment with 5% (v/v) DMSO alone 
resulted in an 11% decrease in cell viability.
When the above experiments were extended to com-
pound 8, no significant DNA damage in human blood 
cells (p > 0.1) was detected in relation to the solvent-
control (Fig. 3). In addition, no significant differences in 
the percentage of cells in the four classes of DNA dam-
age (Fig. 4) were observed. When cell viability studies 
were conducted, no cytotoxicity in human blood cells 
was observed. Together, these results clearly indicated 
a genotoxic negative result for compound 8 and a geno-
toxic positive, concentration-dependent result that was 
not associated with cytotoxicity to human blood cells for 
compound 7 (Table).
The HOMO energies, -9.42 and -9.62 eV, and LUMO 
energy, -1.64 and -1.72 eV, were very similar for both 
compounds 7 and 8 (Fig. 5). From the electronic distri-
bution perspective, it is difficult to explain the discrep-
ancies in the behaviours of compounds 7 and 8.
From a structural viewpoint, a more detailed analysis 
of the molecular interactions between these compounds 
and the receptor binding site was performed based on 
a homology model for the TbNTR. Sequence alignment 
between the targets and the templates resulted in identity 
values of 26% and 24% for 2B67 and 1YKI, respectively. 
In contrast, sequence alignment between the templates 
revealed that despite these proteins not having very sim-
ilar sequences (24% identity and 40% similarity), their 
structural alignment resulted in a root mean square de-
viation of 3.73 Å, indicating that a considerable degree 
of conservation exists in their secondary structures and 
overall shapes. According to the PROCHECK program 
(Laskowski et al. 1993), both chains of the TbNTR ho-
modimer homology model displayed 90% of their resi-
dues in the allowed regions of the Ramachandran plot. 
The QMEAN6 (Benkert et al. 2009) scores for chains A 
and B of the homodimer were 0.52 and 0.57, respective-
ly, indicating average quality values for both structures. 
In addition, the DFIRE (Zhou & Zhou 2002) pseudoen-
ergy values were -250.17 (chain A) and -256.57 (chain 
B), respectively, revealing energy optimised structures. 
Finally, the coordinates of the FMN cofactor were trans-
ferred from the 1YKI template into the TbNTR homol-
ogy model, based on the sequence conservation of the 
neighbouring residues. The whole system was energy 
minimised with 10,000 steps by applying steepest de-
scent algorithm.
The interaction energies of docked ligands within the 
active site of the TbNTR suggested a stronger interaction 
with compound 8 than that of compound 7. According to 
the Vina score function, the minimum binding energy 
values were -5.8 and -7.2 kcal/mol for compounds 7 and 
8, respectively. The proposed plausible binding mode of 
compound 7 inside the TbNTR is shown in Fig. 6. It is 
noteworthy that the lower energy-docked solutions for 
both compounds projected their nitroimidazole rings 
into the bulk. This observed orientation was similar to 
what was observed for the bactericidal nitrofurazone in 
the binding site of the E. coli NTR (which was used as a 
template) (Race et al. 2005). In addition, Van der Waals 
contacts were observed between compound 8 and the 
Leu197 and Tyr200 residues in chain B. The nitroimi-
dazole ring was positioned over the polar ring of FMN 
while the aminotriazole ring was located over the cen-
tral ring of the cofactor. The secondary amine hydrogen 
Fig. 5: electronic distributions for megazol (7) and compound 8 [5-(1-
methyl-5-nitro-1H-imidazol-2-yl)-4H-1,2,4-triazol-3-amine]. Red in-
dicates an electron-rich highest occupied molecular orbital (HOMO) 
[or lowest unoccupied molecular orbital (LUMO)] region, while blue 
indicates an electron-poor region. Semi-empirical calculations were 
performed using the MOPAC2009 software package (OpenMOPAC.
net) with the semiempirical PM3 method and full geometric optimisa-
tion. The ejection fraction routine was used for the minimum search.
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atom bound to the Phe125 carbonyl oxygen and Thr227 
hydroxyl in chain A. It is noteworthy that this H-bond is 
equivalent to the one in the 1YKI PDB structure, where 
the nitrofurazone antibiotic hydrogen bonds to the Thr41 
of the E. coli NTR. In addition, the nitrogen atoms (1 and 
2) of the triazole ring formed hydrogen bonds with one 
OH group of FMN (Fig. 6A).
In contrast, the thiadiazole ring was located over the 
polar ring of FMN and the NH2 was attached (hydro-
gen bonded) to one of the hydroxyl groups of the co-
factor and the oxygen atoms belonging to the side chain 
of Glu266. Similar to compound 8, compound 7 was 
encompassed by both chains of the TbNTR homodimer 
and its nitro group was more exposed to the solution than 
that of compound 8, projecting itself into the Tyr199 and 
Tyr200 residues. Finally, we observed that the replace-
ment of the triazole ring sulphur atom by a NH group al-
lowed compound 8 to penetrate further into the binding 
site, enhancing the possibility of making more specific 
interactions with the receptor (Fig. 6B).
In conclusion, we compared the trypanocidal activity 
of compound 7 with its 4H-1,2,4-triazole 8 bioisostere 
and demonstrated that both compounds were effective 
substrates for the TbNTR. A homology structural model 
of the TbNTR was built and used for docking assays of 
compounds 7 and 8. The results of the molecular docking 
assays confirmed an energetic preference for the binding 
of bioisostere 8 over compound 7 within the active site of 
the nitroreductase. Additionally, in agreement with the 
results obtained by the enzymatic assay, the results also 
revealed that the anti-trypanosomal activity is not likely 
related to the isolated action on the TbNTR enzyme as 
compound 8 had a superior affinity for this target than 
compound 7.
The disparities in the trypanocidal activity of the two 
compounds may indicate differences in their uptake by 
the parasite or may suggest that once in the pathogen, the 
two compounds can have distinct mechanisms of action.
We have also observed that the replacement of the 
sulphur atom of the triazole ring with a NH group has 
allowed that compound 8 can penetrate further into the 
binding site, enhancing the possibility of making more 
specific interactions with the receptor.
Although the genotoxic properties of compound 7 
have been well documented (Ferreira & Ferreira 1986, 
Nesslany et al. 2004) and assumed to be due to the nitro 
group, we conclude that the absence of genotoxicity ob-
served for the nitro derivative compound 8 demonstrates 
that this group is not solely responsible for this activ-
ity. The present study will help to guide future research 
focusing on obtaining new nitroimidazoles with high 
trypanocidal activity, such as compound 7, that are not 
genotoxic, like compound 8. Our found is not a “nega-
tive result”, but can really contribute with the better 
understanding of the importance of nitro group in the 
medicinal chemistry of nitroimidazoles.
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